The FDA advisory panel recommended that compounding pharmacies be allowed to manufacture the peptides epitalon and semax, and recommended against manufacturing emideltide.
2026-07-24 → 2026-07-25
Standing
lens: Evidence-weighted Structural
No belief has been computed for this claim under Structural yet.
What bears on it
Nothing supports or challenges this claim yet — untested, which is not the same as refuted.
Voices
- STAT independent
Voices are counted, never weighed. How many people say a thing is structure worth seeing; it is not, by itself, a reason to believe it.
What the documents actually said
The verbatim text each extraction read before resolving it into this canonical claim. Quoted, never republished.
- The FDA advisory panel recommended that compounding pharmacies be allowed to manufacture the peptides epitalon and semax, and recommended against manufacturing…
A Food and Drug Administration advisory panel recommended on Friday that compounding pharmacies be allowed to manufacture the peptides epitalon and semax, but narrowly voted to recommend against manufacturing emideltide.
Sources
Who and what it involves
Origin: extracted from FDA advisory panel narrowly rejects compounding of one peptide, backs two others · 2026-09-11 07:34